Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Stage of Development | 8 | 1 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Therapy Area | 9 | 1 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Indication | 10 | 1 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Unknown Stage Products | 13 | 1 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Companies | 14 | 2 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Products under Development by Universities/Institutes | 16 | 2 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Companies Involved in Therapeutics Development | 24 | 5 |
| Merck &Co., Inc. | 24 | 1 |
| SciFluor Life Sciences, LLC | 25 | 1 |
| Tissue Therapies Limited | 26 | 1 |
| TWi Pharmaceuticals, Inc. | 27 | 1 |
| Vascular Pharmaceuticals, Inc. | 28 | 1 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Drug Profiles | 29 | 18 |
| A-11 Drug Profile | 29 | 1 |
| AC-301 Drug Profile | 30 | 1 |
| C-16Y Drug Profile | 31 | 1 |
| cilengitide Drug Profile | 32 | 2 |
| MK-0429 Drug Profile | 34 | 1 |
| OCU-200 Drug Profile | 35 | 1 |
| Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma Drug Profile | 36 | 1 |
| Proagio Drug Profile | 37 | 1 |
| RSF-201 Drug Profile | 38 | 1 |
| SF-0166 Drug Profile | 39 | 1 |
| SOM-0777 Drug Profile | 40 | 1 |
| tetraiodothyroacetic acid Drug Profile | 41 | 1 |
| VF-001 Drug Profile | 42 | 1 |
| VF-002 Drug Profile | 43 | 1 |
| VF-003 Drug Profile | 44 | 1 |
| VF-004 Drug Profile | 45 | 1 |
| VPI-2690B Drug Profile | 46 | 1 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Dormant Projects | 47 | 4 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Discontinued Products | 51 | 1 |
| Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Featured News &Press Releases | 52 | 8 |
| May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find | 52 | 1 |
| May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology | 53 | 1 |
| Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin av 3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease | 53 | 1 |
| Feb 11, 2016: Ocugen Announces Patent Allowance For Ocu-200 | 54 | 1 |
| Dec 17, 2015: Tissue Therapies Provides FDA Regulatory Progress Update | 54 | 1 |
| Feb 25, 2013: Merck Serono Announces Phase III Trial Of Cilengitide Did Not Meet Primary Endpoint In Patients With Newly Diagnosed Glioblastoma | 55 | 2 |
| Jun 09, 2011: Merck Serono Completes Patient Enrollment For Cilengitide s Pivotal Phase III Trial CENTRIC | 57 | 1 |
| Jun 05, 2010: EMD Serono Announces Long-Term Follow-up Data From Cilengitide Study In Glioblastoma Patients | 57 | 1 |
| May 31, 2009: Study Shows Cilengitide Increased Overall Survival In Patients With Glioblastoma | 58 | 1 |
| Mar 16, 2009: Merck Serono Expands Cilengitide Development Program | 59 | 1 |
| Jan 01, 2004: | 59 | 1 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |